🔗 Share this article World Health Organization Sounds Concern Over Critical Shortage of Obesity Jabs Under a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it issues its inaugural recommendations on the therapies. With over a billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments. Per projections, more than two billion could be living with obesity by 2030 if no action is taken. "Our new guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to broad availability to the jabs that can aid individuals in losing considerable body mass, explains the body. GLP-1 Therapy Shortage Despite the current most favorable scenario, the supply of such drugs could only cover around 100 million people – fewer than 10% of the global need, per the health organization. The recommendation calls on governments and firms to expand availability, via approaches like patent sharing. The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several nations in 2026. The Way Weight-Loss Drugs Function GLP-1 drugs replicate a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so individuals eat less. People usually start to lose weight after several weeks of beginning the regular doses. Research suggests users may regain a significant portion after a year of stopping the drug, when their usual food cravings resume. To be overweight or obese increases your risk for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and specific cancers. Excess weight impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
Under a tenth of individuals that would benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it issues its inaugural recommendations on the therapies. With over a billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments. Per projections, more than two billion could be living with obesity by 2030 if no action is taken. "Our new guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to broad availability to the jabs that can aid individuals in losing considerable body mass, explains the body. GLP-1 Therapy Shortage Despite the current most favorable scenario, the supply of such drugs could only cover around 100 million people – fewer than 10% of the global need, per the health organization. The recommendation calls on governments and firms to expand availability, via approaches like patent sharing. The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several nations in 2026. The Way Weight-Loss Drugs Function GLP-1 drugs replicate a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so individuals eat less. People usually start to lose weight after several weeks of beginning the regular doses. Research suggests users may regain a significant portion after a year of stopping the drug, when their usual food cravings resume. To be overweight or obese increases your risk for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and specific cancers. Excess weight impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.